Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of XC243 in Healthy Volunteers
NCT05628116Phase 1Completed
- Sponsor
- PHARMENTERPRISES LLC
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of XC243 in pain and cystitis (7 arms), sponsored by PHARMENTERPRISES LLC. Primary endpoint: Number of Adverse events (AEs) per treatment arm. Started Sep 2022; status: completed.
02
Drugs
XC243
03
Conditions
paincystitis
Beyond the preview
Go deeper on NCT05628116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05628116.